• Aluminium pouches with a Microwell Plate coated with monoclonal antibody to human IL-32α(8x12)
• 2 vials human IL-32α Standard lyophilized, 500 pg/ml upon reconstitution
• 2 vials concentrated Biotin-Conjugate anti-human IL-32α monoclonal antibody
• 2 vials Streptavidin-HRP solution
• 1 bottle Standard /sample Diluent
• 1 bottle Biotin-Conjugate antibody Diluent
• 1 bottle Streptavidin-HRP Diluent
• 1 bottle Wash Buffer Concentrate 20x (PBS with 1% Tween-20)
• 1 vial Substrate Solution
• 1 vial Stop Solution
• 3 pieces Adhesive Films
• package insert

IL-32α is the shortest and most abundant of four potential splice variants of the proinflammatory cytokine IL-32 (previously called NK4) with a predicted unmodified size of 15 kDa. Potential modifications include myristoylation and N-glycosylation. The IL-32α shows increased potency at inducing CXCL2/MIP-2 and CXCL8 expression in PBMC relative to uncleaved IL-32α. Transfected IL-32α was more likely to be cellassociated as compared to IL-32β, suggesting an intracellular function. IL-32 is induced by mitogens in peripheral lymphocytes, by IFNγ in epithelial cells, or by IL-12 with IL-18 in NK cells and in turn induces cytokine expression.

Dahl, C. A.et al. (1992) J Immunol. 148: 597.

Kim, S. H. et al. (2005) Immunity. 22: 131.

Goda, C. et al. (2006)Int Immunol. 18:233.

Dinarello, C. A. et al. (2006)Ann Rheum Dis. 65: 61.

Novick, D. et al. (2006)Proc Natl Acad Sci U S A.103:3316.

Netea, M. G. et al. (2008) Proc Natl Acad Sci U S A. 105: 3515.

Joosten, L. A. et al. (2006)Proc Natl Acad Sci U S A. 103: 3298.

Nold, M. F. et al. (2008)J Immunol.181: 557.

Rasool, S. T. et al. (2008)Immunol Lett.117: 161.

Netea, M. G. et al. (2006)PLoS Med. 3:e277.